You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 14, 2025

CLINICAL TRIALS PROFILE FOR DEPO-MEDROL


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Depo-medrol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed National Cancer Institute (NCI) Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed M.D. Anderson Cancer Center Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002831 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Completed National Cancer Institute (NCI) Phase 1/Phase 2 1995-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002831 ↗ Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia Completed M.D. Anderson Cancer Center Phase 1/Phase 2 1995-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002833 ↗ Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 1994-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833 ↗ Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia Completed M.D. Anderson Cancer Center Phase 2 1994-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002835 ↗ Combination Chemotherapy in Treating Patients With Lymphoma Completed National Cancer Institute (NCI) Phase 3 1995-10-30 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Depo-medrol

Condition Name

Condition Name for Depo-medrol
Intervention Trials
Leukemia 15
Osteoarthrosis 6
Acute Lymphoblastic Leukemia 6
Graft Versus Host Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Depo-medrol
Intervention Trials
Leukemia 22
Leukemia, Lymphoid 16
Precursor Cell Lymphoblastic Leukemia-Lymphoma 15
Syndrome 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Depo-medrol

Trials by Country

Trials by Country for Depo-medrol
Location Trials
United States 420
Canada 42
China 16
Denmark 14
Australia 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Depo-medrol
Location Trials
Texas 30
California 21
Ohio 17
New York 16
Indiana 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Depo-medrol

Clinical Trial Phase

Clinical Trial Phase for Depo-medrol
Clinical Trial Phase Trials
Phase 4 18
Phase 3 20
Phase 2/Phase 3 6
[disabled in preview] 73
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Depo-medrol
Clinical Trial Phase Trials
Completed 57
Recruiting 18
Active, not recruiting 12
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Depo-medrol

Sponsor Name

Sponsor Name for Depo-medrol
Sponsor Trials
National Cancer Institute (NCI) 20
M.D. Anderson Cancer Center 16
Bispebjerg Hospital 7
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Depo-medrol
Sponsor Trials
Other 130
Industry 39
NIH 32
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

DEPO-MEDROL (Methylprednisolone): Clinical Trials, Market Analysis, and Projections

Introduction

DEPO-MEDROL, a formulation of methylprednisolone acetate, is a widely used corticosteroid with broad applications in various medical conditions. This article will delve into recent clinical trials, market analysis, and future projections for this drug.

Clinical Trials Update

Methylprednisolone in Acute Ischemic Stroke

A significant recent clinical trial is the MARVEL (Methylprednisolone as Adjunctive to Endovascular Treatment for Acute Large Vessel Occlusion) trial. This investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial was conducted at 82 comprehensive stroke centers in China. The trial involved 1680 patients with acute ischemic stroke who were randomly assigned to receive either intravenous methylprednisolone at 2 mg/kg/day or a placebo for three days, in addition to endovascular thrombectomy.

The results showed that the addition of methylprednisolone did not significantly improve the overall disability outcomes as measured by the modified Rankin Scale (mRS) at 90 days. However, there was a lower mortality rate (23.2% vs 28.5%) and a lower rate of symptomatic intracranial hemorrhage (8.6% vs 11.7%) in the methylprednisolone group compared to the placebo group[1].

Indications and Usage

DEPO-MEDROL is indicated for a wide range of conditions, including:

  • Allergic States: Control of severe or incapacitating allergic conditions such as asthma, atopic dermatitis, and drug hypersensitivity reactions.
  • Dermatologic Diseases: Treatment of conditions like bullous dermatitis herpetiformis, exfoliative erythroderma, and severe erythema multiforme.
  • Rheumatic Disorders: Adjunctive therapy for acute gouty arthritis, rheumatoid arthritis, and psoriatic arthritis.
  • Other Conditions: Use in acute nonspecific tenosynovitis, epicondylitis, and systemic lupus erythematosus[3][4].

Market Analysis

Market Size and Growth

The global methylprednisolone market is projected to grow significantly over the coming years. By 2027, the market size is estimated to reach $917.4 million, growing at a Compound Annual Growth Rate (CAGR) of 3.4% from 2022 to 2027. This growth is driven by the increasing prevalence of autoimmune disorders and other inflammatory diseases[5].

Market Segmentation

The methylprednisolone market can be segmented by product type, application, and geography.

  • Product Type: The market is primarily split into infusion type and oral type. The infusion type is further segmented into sublingual films and fully dissolving dental/buccal films[5].
  • Application: The drug is used in various medical conditions, with rheumatic disorders being the fastest-growing segment due to rising risk factors such as old age, smoking, and obesity[5].
  • Geography: North America holds a dominant market share, but the Asia-Pacific region is expected to offer lucrative growth opportunities due to increasing healthcare expenditure and awareness about better medical conditions[5].

Distribution Channels

The market is segmented into offline and online retail channels, with offline retail holding a dominant share due to the urgent nature of allergic conditions that often require immediate treatment in hospital settings[5].

Market Drivers

Growing Prevalence of Autoimmune Disorders

The increasing prevalence of autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis is a significant driver for the methylprednisolone market. These conditions require long-term management, which includes the use of corticosteroids like methylprednisolone[5].

Rising Healthcare Expenditure

Increased healthcare expenditure, particularly in regions like Asia-Pacific, is driving the demand for better medical treatments, including the use of methylprednisolone. For instance, India's healthcare expenditure rose by up to 137% in 2021, indicating a growing market[5].

Market Challenges

Side Effects and Contraindications

Methylprednisolone, like other corticosteroids, has several side effects and contraindications. It is contraindicated in patients with known hypersensitivity to the product, idiopathic thrombocytopenic purpura, and systemic fungal infections. These limitations can affect its market growth[3][4].

Regulatory Scrutiny

Clinical trials and regulatory approvals are crucial for the market success of any drug. The MARVEL trial's findings, for example, may influence future regulatory decisions and clinical guidelines for the use of methylprednisolone in acute ischemic stroke[1].

Future Projections

Market Growth Opportunities

The Asia-Pacific region is expected to offer significant growth opportunities due to increasing awareness and healthcare expenditure. The growing geriatric population and rising obesity rates are also expected to drive the demand for methylprednisolone in managing related health conditions[5].

Competitive Landscape

The global methylprednisolone market is competitive, with key players such as ENDO, Pharmacia, TEVA, SANDOZ, Pfizer, and JUBILANT CADISTA. These companies are expected to continue innovating and expanding their product lines to capture a larger market share[2].

Key Takeaways

  • Clinical Trials: Recent trials like the MARVEL trial have shown mixed results, highlighting the need for further research on the efficacy of methylprednisolone in specific conditions.
  • Market Growth: The global methylprednisolone market is projected to grow at a CAGR of 3.4% from 2022 to 2027, driven by increasing prevalence of autoimmune disorders and rising healthcare expenditure.
  • Market Segmentation: The market is segmented by product type, application, and geography, with North America currently holding a dominant share but Asia-Pacific offering future growth opportunities.
  • Challenges: Side effects, contraindications, and regulatory scrutiny are key challenges that need to be addressed.

FAQs

What are the primary indications for DEPO-MEDROL?

DEPO-MEDROL is indicated for allergic states, dermatologic diseases, rheumatic disorders, and other inflammatory conditions.

What were the findings of the MARVEL trial?

The MARVEL trial found that adjunctive methylprednisolone therapy did not significantly improve overall disability outcomes in patients with acute ischemic stroke but did reduce mortality and symptomatic intracranial hemorrhage rates.

What is the projected market size of methylprednisolone by 2027?

The global methylprednisolone market is estimated to reach $917.4 million by 2027.

Which region is expected to offer the most growth opportunities for methylprednisolone?

The Asia-Pacific region is expected to offer significant growth opportunities due to increasing healthcare expenditure and awareness.

What are the main side effects and contraindications of methylprednisolone?

Methylprednisolone has several side effects and is contraindicated in patients with known hypersensitivity, idiopathic thrombocytopenic purpura, and systemic fungal infections.

Sources

  1. JAMA Network: Methylprednisolone as Adjunct to Endovascular Thrombectomy for Acute Ischemic Stroke.
  2. PharmiWeb: Global Methylprednisolone Market 2020 – Industry Dynamics, Segmentation and Competition Analysis 2025.
  3. Pfizer: DEPO-MEDROL (methylprednisolone acetate injectable suspension) Label.
  4. FDA: DEPO-MEDROL (methylprednisolone acetate injectable suspension) Label.
  5. IndustryARC: Methylprednisolone Market - Forecast(2024 - 2030).
Last updated: 2025-01-04

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.